Integrative medicine for lymphoma survivors
Official title: Effectiveness of Integrative Medicine Treatments in Lymphoma Survivors
Run by Bnai Zion Medical Center · NCT05982223 · Data updated 2026-11-12
This study tests if combining traditional treatments with therapies like acupuncture and mind-body practices can help lymphoma survivors feel better and improve their quality of life after treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | Bnai Zion Medical Center Government |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Haifa) |
| Status | Recruiting |
| Started | July 13, 2023 |
| Main results expected | July 2028 |
| Study ends | July 2028 |
| Registry record updated | October 2, 2026 |
| Trial ID | NCT05982223 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are lymphoma survivors aged 18 and older who have completed chemotherapy or biological treatment and are in remission for less than one year.
✕Probably not a fit
Patients who are not lymphoma survivors or those who have been in remission for over a year may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the effects of integrative treatments, combining conventional and complementary medicine, on the quality of life of lymphoma survivors. It focuses on patients who have undergone chemotherapy or biological treatments and are experiencing lingering symptoms and quality-of-life impairments. The interventions include acupuncture, mind-body therapy, touch therapy, movement therapy, and herbal supplements. The goal is to assess whether these integrative approaches can alleviate symptoms and improve overall well-being in this patient population.
Why it matters
Potential benefit: If successful, this study could significantly enhance the quality of life for lymphoma survivors by providing effective symptom relief and support.
How similar studies have gone: While many studies have shown success in using complementary medicine for breast cancer survivors, few have specifically examined its impact on lymphoma survivors, making this approach relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients diagnosed with a lymphoproliferative disease * Aged 18 years or older * Received chemotherapy, biological treatment or both for treating the lymphoproliferative disease * Defined in remission for less than one year by the haemato-oncologist (maintenance therapy is authorized) * Can respond to questionnaires * Signed informed consent Exclusion Criteria: None
Where it's running
-
Bnai Zion Medical Center
Haifa, Israel Recruiting
Study contacts
- Principal investigator: Ilana Levy Yurkovski, MD — Bnai Zion Medical Center
- Study coordinator: Dana Weizer
- Email: dana.weizer@b-zion.org.il
- Phone: 972-543295952
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
LB-208: a new oral treatment for adults with advanced solid tumors or lymphoma
This early study tests whether LB-208, taken once daily by mouth, is safe for adults with advanced solid tumors or lymphoma who have exhausted standard treatments.
-
Tailored exercise program to improve quality of life for adults with hematologic cancers
This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.
-
CD19/CD22 CAR-T consolidation after second-line therapy for high-risk aggressive B-cell lymphoma
This trial tests whether CD19/CD22 CAR-T cell therapy given after a second-line response can help people with high-risk aggressive B-cell lymphoma stay in remission.
-
Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia
This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.
-
Genetics of Blood Cancers in the U.S. population
This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.
-
Glofit-GemOx Bridging to Liso-cel for Relapsed/Refractory Large B-Cell Lymphoma
This trial tests whether a bridging therapy with Glofit-GemOx followed by lisocabtagene maraleucel helps people with relapsed or refractory large B-cell lymphoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.